Glucosamine & Chondroitin
Glucosamine sulfate/hydrochloride; Chondroitin sulfate
Popular joint supplements for osteoarthritis with largely disappointing trial evidence.
Mixed evidence
✨Joint & Skin
Evidence tier
Mixed
Research weight
Citations
20 verified / 20
Classification
Joint & Skin
❝
What the evidence says. Conflicting results across studies; benefit uncertain.
What is Glucosamine & Chondroitin?
Glucosamine & Chondroitin (Glucosamine sulfate/hydrochloride; Chondroitin sulfate) is a joint and skin supplement used for may provide a small reduction in knee osteoarthritis pain in some trials, though high-quality studies and major guidelines find little or no benefit over placebo. NutriDex grades the human evidence as Mixed. Glucosamine and chondroitin are among the most widely used dietary supplements for osteoarthritis, particularly of the knee, and are marketed for joint pain, stiffness, and cartilage support. The pivotal NIH-funded GAIT trial found that neither agent alone nor in combination beat placebo for overall knee pain, although an exploratory analysis hinted at possible benefit in patients with moderate-to-severe pain. Subsequent meta-analyses are mixed: some report a small pain reduction for the individual agents (but not the combination), while a 2025 network meta-analysis found effects largely indistinguishable from placebo. On the strength of high-quality data showing lack of efficacy, the 2019 American College of Rheumatology/Arthritis Foundation guideline strongly recommends against using glucosamine, and conditionally or strongly against chondroitin, for knee osteoarthritis. Overall the evidence is best characterized as mixed-to-disappointing, though the supplements are inexpensive and unusually safe, which helps explain their continued popularity.
Purported Benefits
✓May provide a small reduction in knee osteoarthritis pain in some trials, though high-quality studies and major guidelines find little or no benefit over placebo
✓Possible modest benefit in the subgroup of patients with moderate-to-severe knee pain (exploratory GAIT finding, not confirmed)
✓Chondroitin may offer a small short-term improvement in pain and function in some pooled analyses, but on low-quality evidence
✓Generally very well tolerated, with a safety profile comparable to placebo across trials
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Knee osteoarthritis pain reductionPivotal GAIT RCT and 2025 network MA show no benefit over placebo; some MAs find small sub-MCID effects. Major guidelines recommend against. | Mixed | ↔ mixed · small | 6 |
| Pain in moderate-to-severe knee OA subgroupOnly an exploratory, unconfirmed GAIT subgroup plus the MOVES non-inferiority trial; not a prespecified, replicated finding. | Preliminary | ↑ benefit · moderate | 2 |
| Joint-space narrowing (structure modification)A single 3-year glucosamine sulphate RCT and one MA suggest slowed narrowing; not seen for the combination and not symptom-relevant. | Preliminary | ↑ benefit · small | 2 |
| Safety / tolerabilityConsistently well tolerated with adverse events comparable to placebo across many trials; the main established attribute. | Strong | ↑ benefit · large | 3 |
| Lower all-cause/cardiovascular mortalityLarge UK Biobank cohorts show associations only; healthy-user bias and residual confounding preclude causal claims. | Preliminary | ↑ benefit · small | 2 |
Dosing & Compounds
Typical Dose
Typically glucosamine 1,500 mg/day (sulfate or HCl) plus chondroitin sulfate 800-1,200 mg/day, often split across doses; taken for at least 8-12 weeks to assess any benefit.
Active Compounds
Safety & Cautions
Generally well tolerated, with adverse event rates similar to placebo; mild GI upset, nausea, heartburn, and headache are the most common complaints. Glucosamine is commonly derived from shellfish (shrimp/crab shells), so people with shellfish allergy should use a labeled non-shellfish/synthetic source or avoid it. Glucosamine may modestly affect glucose metabolism in theory, so diabetics should monitor blood sugar, though clinical trials have not shown meaningful glycemic harm. Chondroitin is structurally heparin-like and there are case reports and a plausible interaction with anticoagulants/antiplatelets (e.g., warfarin), where it may increase INR and bleeding risk; people on blood thinners should consult a clinician. Not recommended during pregnancy or breastfeeding due to insufficient safety data, and supplement purity/labeling can vary. These products are not a substitute for guideline-based osteoarthritis care; patients with significant or worsening joint pain should seek medical evaluation rather than rely on supplementation. Educational only — always check with your doctor or pharmacist before combining Glucosamine & Chondroitin with any medicine.
Key Studies ★ 20 studies
Systematic review
Calzada-Gonzales 2026
✓ PubMed
Systematic review and meta-analysis of glucosamine supplementation for temporomandibular joint disorders.
Systematic review
Chen 2026
✓ PubMed
Network meta-analysis of metformin, probiotics, krill oil, celecoxib, and glucosamine/chondroitin in the treatment of knee osteoarthritis
Meta-analysis
Journal of Clinical Medicine 2024
✓ Full text
Network meta-analysis of 30 RCTs (5,265 patients) concluded the glucosamine + chondroitin sulfate combination does not produce clinically significant pain reduction in mild-to-moderate knee OA (below MCID of SMD 0.40), whereas glucosamine + omega-3 (SMD -2.59, 95% CI -4.42 to -0.75) and glucosamine + ibuprofen (SMD -2.27, 95% CI -3.73 to -0.82) were most effective.
Meta-analysis
Inflammopharmacology 2024
✓ PubMed
Meta-analysis of 25 RCTs found chondroitin sulfate significantly reduced pain and improved physical function vs placebo and glucosamine sulfate reduced tibiofemoral joint-space narrowing, but the GS+CS combination produced neither pain reduction nor functional improvement (only a non-significant reduction in joint-space narrowing); both well tolerated.
Meta-analysis
Gregori et al. 2018
✓ PubMed
Network meta-analysis (47 RCTs, 22,037 patients) of long-term treatments for knee/hip OA. At ~24 months, glucosamine reduced pain significantly vs placebo (SMD ~ -0.29), chondroitin and the glucosamine+chondroitin combination did not show significant long-term pain benefit over placebo; effect sizes were generally small and below the threshold considered clinically important.
Cochrane systematic review
Cochrane review, 43 trials
✓ Full text
Chondroitin (alone or with glucosamine) produced a small short-term improvement in pain (about 8 points on a 0-100 scale) vs placebo, but the evidence was of low quality and effects shrank in larger, better-conducted trials.
Systematic review and meta-analysis
Meta-analysis of placebo-controlled RCTs
✓ PubMed
Glucosamine (-7.4 mm) and chondroitin (-8.4 mm) each modestly reduced knee OA pain on a 100 mm VAS, but the combination showed no significant effect and neither improved total WOMAC scores.
Network meta-analysis
22 RCTs, 2,777 participants
✓ Full text
A network meta-analysis found glucosamine and chondroitin sulfate produced minimal changes in WOMAC pain and total scores, with confidence intervals crossing zero, indicating effects largely indistinguishable from placebo.
network meta-analysis
Network meta-analysis, 10 trials, n=3,803
✓ PubMed
In this BMJ network meta-analysis of hip/knee OA, glucosamine (-0.4 cm), chondroitin (-0.3 cm), and the combination (-0.5 cm) reduced pain on a 10 cm VAS versus placebo, but none reached the prespecified minimal clinically important difference of -0.9 cm, indicating no clinically relevant benefit.
systematic review
Systematic review of clinical studies
✓ PubMed
This systematic review in Osteoarthritis and Cartilage found mixed and inconclusive evidence on whether oral glucosamine alters glucose metabolism in humans, with no clear adverse effect on fasting glucose or insulin sensitivity, but called for more data in people at risk of impaired glucose homeostasis.
Clinical guideline
Clinical practice guideline
✓ Source
The 2019 ACR/Arthritis Foundation guideline strongly recommends against glucosamine and against the glucosamine-chondroitin combination for knee, hip, and hand OA, citing high-quality evidence of lack of meaningful benefit.
clinical guideline
Clinical practice guideline (60 interventions reviewed)
✓ PubMed
The 2019 OARSI guideline strongly recommends against glucosamine and against chondroitin for knee, hip, and polyarticular osteoarthritis, citing lack of efficacy and low-quality evidence.
Randomized controlled trial
n=1,583 (RCT, 24 wk)
✓ PubMed
In the GAIT trial, glucosamine, chondroitin, or their combination did not significantly reduce overall knee OA pain vs placebo, though an exploratory subgroup with moderate-to-severe pain showed possible benefit from the combination.
randomized controlled trial
RCT, n=212, 3 years
✓ PubMed
In this 3-year Lancet trial, glucosamine sulphate 1500 mg/day prevented joint-space narrowing (-0.06 mm vs -0.31 mm with placebo) and modestly improved WOMAC symptoms, suggesting a possible structure-modifying effect in knee OA.
randomized controlled trial
RCT (MOVES), n=606, 6 months
✓ PubMed
In this double-blind non-inferiority trial, chondroitin sulfate plus glucosamine hydrochloride reduced WOMAC pain by ~50% and was comparable (non-inferior) to celecoxib 200 mg/day over 6 months in patients with moderate-to-severe knee OA.
RCT
Clegg et al. (GAIT) 2006
✓ PubMed
Landmark NIH multicenter double-blind RCT (N=1583) of glucosamine HCl 1500 mg, chondroitin sulfate 1200 mg, the combination, celecoxib, or placebo for knee OA over 24 weeks. Neither glucosamine, chondroitin, nor the combination significantly reduced pain in the overall cohort vs placebo; an exploratory subgroup with moderate-to-severe baseline pain showed benefit from the combination (79.2% vs 54.3% placebo responders, P=0.002).
Review
Liu 2026
✓ PubMed
O-GlcNAcylation at the tumor-immune interface: a metabolic post-translational code driving immune evasion and therapy resistance in cancer
cohort study
Prospective cohort, n=466,039 (UK Biobank, ~7 yr)
✓ PubMed
Habitual glucosamine use was associated with lower risk of total cardiovascular disease events (HR 0.85, 95% CI 0.80-0.90) and CVD death (HR 0.78, 95% CI 0.70-0.87) compared with non-users, an observational association not establishing causation.
cohort study
Prospective cohort, n=495,077 (UK Biobank, median 8.9 yr)
✓ PubMed
Regular glucosamine use was associated with lower all-cause mortality (HR 0.85, 95% CI 0.82-0.89) and modestly lower cancer mortality (HR 0.94, 95% CI 0.88-0.99), though residual confounding and healthy-user bias likely contribute.
government health body
NIH/NCCIH evidence summary
✓ Source
NCCIH concludes it remains uncertain whether glucosamine and chondroitin meaningfully help knee osteoarthritis symptoms, noting inconsistent trial results and even less evidence for joints other than the knee.